21 research outputs found

    Clinical and virologic outcomes over duration on ART, ARV-naïve patients.

    No full text
    <p>A) median CD4+ cell count (cells/mm<sup>3</sup>) over time on ART; and, B) percentage of patients with virologic suppression (≤400 copies/mL) over time on ART.</p

    Characterization of treatment failure over time.

    No full text
    <p>A) Virologic and immunologic failure rates over duration on ART, 95% CI; and, B) Percentage of patients with virologic failure within first 18 months on ART by enrollment year.</p

    Detection of EBOV antibodies, Lagos, Nigeria.

    No full text
    <p>(A) Sera samples from 3 EVD survivors, 10 documented EVD contacts, and 6 control HCWs were subjected to LFn-EBOV-GP1 and LFn-EBOV-sGP Western blot analysis. +, positive control. Molecular size marker units are kDa. EVD, Ebola virus disease. Control HCWs, control healthcare workers.</p
    corecore